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More than 750,000 of the UK population suﬀer from some form of cognitive impairment and dementia. Of these, 5–20% will
have Dementia with Lewy Bodies (DLB). Clinico-pathological studies have shown that it is the low frequency of DLB clinical core
features that makes the DLB diagnosis hardly recognisable during life, and easily misdiagnosed for other forms of dementia. This
has an impact on the treatment and long-term care of the aﬀected subjects. Having a biochemical test, based on quantiﬁcation of
a speciﬁc DLB biomarker within Cerebrospinal Fluid (CSF) could be an eﬀective diagnostic method to improve the diﬀerential
diagnosis. Although some of the investigated DLB CSF biomarkers are well within the clinical criteria for sensitivity and speciﬁcity
(>90%), they all seem to be confounded by the contradictory data for each of the major groups of biomarkers (α-synuclein, tau
andamyloidproteins).However,acombinationofCSFmeasuresappeartoemerge,thatmaywellbeabletodiﬀerentiateDLBfrom
other dementias: α-synuclein reduction in early DLB, a correlation between CSF α-synuclein and Aβ42 measures (characteristic
for DLB only), and t-tau and p-tau181 proﬁle (diﬀerentiating AD from DLB).
1.Introduction
Presently, in the United Kingdom (UK), it is estimated that
over 100,000 people have been diagnosed with Dementia
with Lewy Bodies (DLB), accounting for 15–20% of the total
number of recorded cases of dementia. By 2050, up to 1.8
million UK inhabitants will be aﬀected by dementia [1], thus
raising the number of DLB suﬀerers by 3-fold. These ﬁgures
inevitably reﬂect the rapid increase in the ageing populations
in UK and Europe. Thus, according to the National Oﬃce
of Statistics (2009), by 2033, 23% of people in UK will be
aged 65 or over, and of them 15–25% will have some form
of cognitive impairment.
1.1. DLB Clinical Symptomatology. Clinically, DLB is charac-
terised by ﬂuctuation of cognitive abilities alongside distinc-
tive psychopathological symptoms, including recurrent, reg-
ular visual hallucinations and delusions [2]. Neurologically,
25–50% of the DLB patients have extrapyramidal symp-
tomatology, including rigidity and bradykinesia, alongside
hypophonic speech, masked facies, stooped posture, and a
slow and shuﬄing gait, whereas the resting tremor is less
common [3, 4].
A diagnosis of DLB requires presence of at least two core
features (Table 1): ﬂuctuating cognition; deﬁnite, regular
hallucinations; or spontaneous parkinsonian movement dis-
orders (present in 78% of DLB patients [4, 5]). In addition,
suggestive features of the probable DLB diagnosis include
RapidEyeMovement(REM)sleepbehaviourdisorder,severe
neurolepticsensitivity,andlowdopaminetransporteruptake
in basal ganglia as demonstrated by SPECT and/or PET
imaging [5]. In studies using postmortem diagnosis of DLB
as the gold standard, an appropriate diagnosis of DLB can be
made with a sensitivity of 78–83% and a speciﬁcity of 85–
95% (using [3] clinical criteria, [6, 7]), with the presence of
visual hallucinations early in the course of dementia being a
strongpredictorofDLBatautopsy[8].However,thesevalues
areachieved whenthecriteria areusedin the specialistclinic,
and thus should be considered as a maximal rather than
an average value. Indeed the sensitivity and speciﬁcity for2 International Journal of Alzheimer’s Disease
Table 1: Clinical diagnostic criteria for DLB.
Core features Features supportive of diagnosis
A progressive,
signiﬁcant
cognitive decline
Repeated falls
Fluctuations in
cognition
Syncope
Recurrent,
well-formed visual
hallucinations
Transient loss of consciousness
Spontaneous
motor features of
parkinsonism
Neuroleptic sensitivity
Systemized delusions
Hallucinations in other modalities
Adapted from Mckeith et al. [5].
DLB diagnosis appear to be somewhat lower when related to
subjects coming from hospital environment, with sensitivity
and speciﬁcity being 60% and 85%, respectively [9].
1.2. Diﬀerentiation of DLB from Other Dementias. In
the clinical setting DLB is commonly misdiagnosed as
Alzheimer’s Disease(AD)orParkinson’s Disease (PD)dueto
their overlapping clinical symptoms [10]. Diﬀerential diag-
nosis is essential, as around 50% of DLB patients are hyper-
sensitive to conventional antipsychotic medication have
worsening delusions and exacerbated motor symptoms [11].
The diagnosis of DLB, probable or possible dementia of
AD, and vascular dementia (VaD) is largely based on clin-
ical and neuropsychological assessment, using the current
diagnostic criteria for diﬀerent dementias (DSM-IV-TR and
speciﬁc criteria for each disorder, e.g., NINCDS/ADRDA for
AD, NINDS/AIREN for VaD, and International Consensus
Criteria for DLB, not included in DSM-IV-TR criteria). The
validity and reliability of these existing criteria have relatively
good speciﬁcity, but low sensitivity for detecting distinct
typesofthedementingprocess,makingthemoflimitedvalue
for routine clinical practice.
The neuroradiological investigations also have limita-
tions in diﬀerentiating distinct types of dementia since many
dementiasuﬀerershaveadegreeofgeneralisedbrainatrophy,
ventriculardilatation, whitematterlesions,and/orischaemic
(sub)cortical changes, though a recent study showed that
hippocampal atrophy [12]m a yd i ﬀerentiate DLB from AD
and VaD. HMPAO SPECT occipital lobe hypoperfusion,
largely thought to be characteristic for DLB [13, 14], has
now been reported to be similarly present to an extent in
other forms of dementia (see [15], reviewed in [16]). The
latest studies measuring brain amyloid load by [ 11C]PIB-
PET also show that not all individuals (89%) with a probable
diagnosis of AD will have an increased amyloid brain load
[17]. Similarly, many DLB subjects have widespread PIB
binding [18], very similar to that seen in AD subjects.
Recent studies have also demonstrated the usefulness of 123I-
metaiodobenzylguanidine (MIBG) myocardial scintigraphy
for the diagnosis of DLB, with marked reduction of cardiac
MIBG uptake being a speciﬁc marker of Lewy body diseases
[19, 20]. However, this procedure is not well validated as
the DaTSCAN-SPECT and remains an unlicensed product
for this indication. We have to highlight that a majority
of the DLB MIBG myocardial scintigraphy studies (with
exception of few, e.g., [21, 22]) have been conducted in Asia,
where heart disease rates are low. Since MIBG myocardial
scintigraphy can be abnormal in heart failure and, to some
extent, severe ischaemic heart disease [23], further studies
areneededtoexploreitsclinicalutilisationforDLBdiagnosis
in the Western countries where the prevalence rates of heart
diseases are much higher (reviewed in [24]).
1.3. Clinico-Neuropathological Correlates of DLB. The simi-
larities between diﬀerent dementias may be explained by the
degree of overlapping pathology [25] and their attributable
risks for cognitive impairment in the elderly [26]. In
particular, coexisting AD pathology (tangles and plaques)
is known to modify clinical symptoms, disease course, and
progression. Thus, DLB individuals with additional neocor-
tical tangles often lack the typical DLB symptom proﬁle
(e.g., lack of core symptoms including ﬂuctuation, visual
hallucinations, and parkinsonism), showing pronounced
memory deﬁcits, severe construction deﬁcit, and a clinical
presentation more characteristic for AD [27, 28]. Similarly,
approximately 70% of DLB patients have neuropathological
changes characteristic of AD, and, clinically, they tend to
have more profound cognitive impairment than those with
“pure” DLB [29]. Correspondingly, at least 59% of AD
patients have LBs, usually restricted to amygdala and sparing
the neocortical regions, with their number increasing as
the disease progresses [30]. Interestingly, the presence of
LBs in the amygdala appears to increase the risk for major
depression in AD by nearly 5-fold [31]. Furthermore, in
AD subjects with similar severity of cognitive impairment at
baseline and comparable Braak stages at autopsy, those with
concomitant neocortical LB pathology (referred to as Lewy
body variant of AD) generally have faster cognitive decline
and accelerated mortality compared to those with “pure” AD
[32].
The neuropathological phenotype, as discussed above,
inﬂuences the clinical presentation in dementia subjects. To
date, the detection of the dementia hallmarks, for example,
tanglesandplaques(forAD),LewybodiesandLewyneurites
(for DLB), and cerebrovascular changes (for VaD), with the
exception ofthe amyloiddeposits, that canbe visualisedwith
PIB) is largely conﬁned to neuropathological assessment.
The ultimate diagnostic goal, therefore, remains to develop
methodology for peripheral detection of the molecular
substrates of the characteristic dementia neuropathological
hallmarks in the cerebrospinal ﬂuid (CSF), blood and blood
derivates and/or urine, to aid the diagnosis, and to monitor
the treatment and progression of the disease process. This is
particularly important in DLB, in the light of the diﬃculties
ofdiagnosingthistypeofdementiainroutineclinicalsetting.
1.4. Diagnostic Tools for DLB. The currently available neu-
roimaging techniques and associated diagnostic tests forInternational Journal of Alzheimer’s Disease 3
Table 2: Cost and time implications of neuroimaging and neuro-
physiological techniques and laboratory tests.
Neuroimaging technique Cost (£) Time (minutes)
CT 80–100 10
MRI 200 30
SPECT 250 15–60
DaTSCAN-SPECT 750 180–360
MIBG myocardial
scintigraphy
500 180
EEG 250 30–45
Blood 2.71 5
Urine 2.12 5
CSF 10 35–40
Abbreviations: CT: computerised tomography; MRI: magnetic reso-
nance imaging; SPECT: single-photon emission computed tomogra-
phy; DaTSCAN-SPECT: [123I]ioﬂupane single-photon emission com-
putedtomography;MIBG: 123I-metaiodobenzylguanidine;EEG:electroen-
cephalogram; CSF: cerebrospinal ﬂuid.
Please note that all costs and times are estimates based on UK NHS data
and do not include professional interpretation of results.
dementia (also used to aid the diagnosis of DLB) represent
a high ﬁnancial burden to Health Care Systems (Table 2).
These costs will inevitably rise on an annual basis in the
light of the rapidly growing population, as reviewed above.
In contrast, tests conducted using samples of bodily ﬂuids
(blood,urine,andCSF)areconsiderablylessexpensive,more
readily available, and patient friendly.
Currently, there are no conclusive methods to test for
DLB, and recommended CSF or other peripheral biomarkers
for routine use in the diﬀerential diagnosis of DLB are lack-
ing. Disease biomarkers, deﬁned as “analytes in biological
samples, (that provide) any measurement that predicts a
person’s disease state or response to a drug...”[ 33] need to
fulﬁl additional criteria, for example, to reﬂect the central
brain pathological process, be reproducible and have over
a 90% speciﬁcity and sensitivity to changes in phenotype
of the condition in order to allow for it to be considered
clinically useful for diagnostic purposes [34]. From a clinical
perspective, a single biomarker oﬀering such diagnostic and
prognostic capability would be the preferable choice.
The CSF contains an abundance of proteins, including
neuron- and astrocyte-related and synapse-speciﬁc proteins
[35]. Among these, the main constituents of Lewy bodies
(α-synuclein), neuroﬁbrillary pathology (tau protein), and
amyloid deposits (Aβ) are detected. Their peripheral CSF
detection provides an opportunity to aid the neurochemical
diagnosis of various dementia processes. This is particularly
important for DLB in the light of the diagnostic diﬃculties
in routine clinical setting, as discussed above.
2.MaterialsandMethods
Thispaperisbasedonliteraturesearchesofseveraldatabases,
including Medline/Ovid, Scopus, Web of Knowledge, and
PubMed. All searches were restricted to literature published
in English between the years 1980–2010 (January 1980–
June 2010). For the purpose of this paper we concentrated
on research studies only on CSF biomarkers and did not
include biomarker studies conducted in bloods and/or
bloodderivates(includingplasma/serum),urine,orgenomic
studies. Review articles were also included if they addressed
either individual CSF biomarkers or in the context of CSF
proteomic studies conducted in DLB and Lewy body disease.
In addition, all articles were reviewed for possible relevant
references. The key words used for these searches were
DementiawithLewybodies(DLB),Lewybody,cerebrospinal
ﬂuid (CSF), biomarkers, proteomics, amyloid protein, tau
protein, and synuclein.
2.1. CSF Biomarkers for DLB
2.1.1. α-Synuclein as a DLB Biomarker
α-Synuclein Processing and Role in DLB. The main compo-
nentsofLBsareamyloid-likeﬁbrilscomposedofα-synuclein
(also referred to as non-amyloid component of plaques or
NACP, synelﬁn, and SYN1). Although the actual function
of α-synuclein remains ambiguous, the protein is involved
in both synaptic rearrangements and, as a chaperone in
the formation of SNARE (Soluble NSF Attachment protein
receptors) complexes, is implicated in the synaptic vesicle
traﬃcking in the human nervous system (reviewed in [36]).
α-Synuclein is a relatively small (112–140 amino acids
in length) presynaptic nonsecreting protein and makes up
around 1% of the total protein within the brain and less
than 0.001% of the CSF proteome [37]. The α-synuclein
phosphorylation, occurring on serine 129, is crucial in
mediating α- s y n u c l e i nn e u r o t o x i c i t ya n di nm o d u l a t i n g
protein structure, including ﬁbrillar aggregation (see [38],
reviewedin[36]).ThehippocampalCA2regionisthoughtto
beespeciallyvulnerabletothisα-synucleinpost-translational
modiﬁcation [39]. Similarly, mutations in the SNCA,o r
Synuclein-Alpha (non-A4 component of amyloid precursor)
gene[40]aswellastheov erpr oductionofα-synuclein[41]in
some rare cases of familial DLB give rise to the characteristic
pathology in DLB, and provide further insights into the
altered processing of this synaptic protein.
Detection of CSF α-Synuclein in DLB. The monomeric,
soluble α-synuclein (molecular weight 14–19kDa), but not
the higher molecular species (e.g., oligomers and polymers,
present in blood and brain tissue), is found in the CSF see
[42, 43]). However, the presence of higher molecular aggre-
gates (>150kDa) consisting of α-synuclein, complement C3
precursor, complement C4-B precursor, and Ig gamma-1
chain -C region in the absence of soluble monomeric α-
synuclein, has also been described [44].
The limited number of currently available studies has
provided rather conﬂicting results regarding the measures of
CSF α-synuclein in DLB subjects: decreased and unchanged
to even elevated levels have all been reported (see Table 3,
[45]). Furthermore, a recent study found that, although
α-synuclein detection in CSF may not be useful for dif-
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were signiﬁcantly correlated with duration of the DLB (P
<.05), but not with the AD [46]. This would suggest that
the reduction of the CSF α-synuclein may reﬂect the extent
of Lewy-related pathology characteristic of more advanced
stages of DLB [47]. It must be noted, though, that the
Noguchi-Shinohara et al. study [46] did not include control
subjects, and as an alternative, a group of “matched” DLB
patients with similar MMSE score results to the AD patients
were included, instead.
α-Synuclein CSF levels appear to be similar in various
dementia types, including DLB, AD, frontotemporal
dementia (FTD) or VaD, and those of control subjects
[48]. However, the ﬁndings for AD subjects were not
conclusive, and lower levels of CSF α-synuclein, compared
to controls, have also been reported (P <.001; Table 3;s e e
[49]). In the latter study, the decrease in α-synuclein in the
CSF of AD subjects was signiﬁcantly associated with the
disease duration, suggesting that it well reﬂects the extent of
advanced AD neuropathology and profound brain synaptic
loss, including α-synuclein as described previously [50].
In contrast to the above studies, Mollenhauer et al.
[51]a n dK a s u g ae ta l .[ 52]r e p o r t e dd i ﬀerences in CSF α-
synuclein levels between AD, PD, DLB, and control subjects.
There was a signiﬁcant decrease in CSF α-synuclein in PD
and DLB individuals, in comparison to the AD and control
groups (P =.025; see [51]) and those with other dementias,
including FTD, PSP, VaD, normal pressure hydrocephalus,
a n du n s p e c i ﬁ e dd e m e n t i a s( P<. 01; see [52]). The α-
synuclein gene (SNCA) duplication, which in some instances
is associated with somewhat more aggressive clinical presen-
tation of both motor and cognitive symptoms [53], appears
not to inﬂuence the α-synuclein expression in the CSF, since
the aﬀected carriers with the DLB/PDD clinical phenotype
haveasimilarCSFα-synucleinlevelsasDLBindividuals[52].
The α-synuclein levels appear not to be associated with
the extent of cognitive impairment (as assessed by MMSE),
DLB, or AD disease duration, age, or gender [52]. However,
the α-synuclein CSF levels are correlated with those of Aβ42
a n dr e s t r i c t e dt oD L Bs u b j e c t s[ 52], suggesting that there
may well be a close relationship between the amyloid and α-
synuclein brain processing and deposits in DLB subjects. In a
recentstudy,thesigniﬁcantreductionintheα-synucleinCSF
levels was present even in DLB subjects with mild dementia
[44], further indicating that lower CSF α-synuclein protein
may be an early marker for the disease.
Methodological Limitations of Available α-Synuclein Analyti-
cal Tools. The reasons as to why various studies are markedly
diﬀerent must be addressed in order to promote better study
designs. Thus, it has been questioned whether the technique
recommended by Tokuda et al. [83]( w h i c hr e q u i r e sc o n -
centration of CSF samples) could lead to inaccuracies. In
addition, the assays used in some of the studies introduced
incubation of the CSF samples for 48 hours at 4◦C. The latter
experimental step is associated with oligomerization of the
α-synuclein in vitro, and thus may be a contributing factor
forboththeobserved decreaseandvariability inthereported
concentration of α-synuclein in CSF.
The choice of immunoprobes (N-terminal end being
moreconsistentlypresentintheCSFthantheC-terminalend
p o r t i o no ft h ep r o t e i n ) ,a sw e l la sd i ﬀerential expression of
distinct α-synuclein isoforms (with a modiﬁed C-terminus)
inageingandneurodegenerativedisorders,mayalsounderlie
thereporteddiﬀerencesinthedetectionofα-synucleininthe
CSF(reviewedin[36,45]).Similarly,theﬁndingsofdecrease
in α-synuclein in DLB as a function of the disease duration
[46] may reﬂect the central neuropathological process of
the disease and the consequent molecular changes associated
with the latter. The duration-dependent decrease in CSF α-
synuclein suggests the extent of α-synuclein aggregates in
DLB [84] and their inability to pass the brain blood barrier
[84, 85]. We have also previously reported a signiﬁcant
depletion of α-synuclein in more advanced stages of AD,
preceded by a transient upregulation of the protein in
both CSF and brain tissue occurring in the Braak stage 4
[45, 50, 86]. Further correlative clinico-neuropathological
studies will need to follow to explore the neuropathological
correlates of the α-synuclein CSF changes in DLB and
associated dementia syndromes.
2.1.2. Tau Protein as a DLB Biomarker
Tau Protein Detection in DLB. The microtubule-associated
Tau Protein represents an integral component of the paired
helical ﬁlaments (PHFs). The truncation of the protein at
Glu391 and/or its phosphorylation (regulated by a number
of kinases) are the crucial step in the self-assembly of the
protein into PHFs, found within various neuroﬁbrillary
structures (e.g., neuroﬁbrillary tangles, neuritic plaques, and
dystrophic neurites; see Figure 1) commonly associated with
many neurodegenerative disorders, such as AD and DLB
[87].
Tau proteins are also present in the CSF and have
beenextensivelyinvestigatedinvariousdementiasyndromes.
However, this protein (which is also referred to as Beta-2
transferrin or desialyated transferrin) is not routinely found
in blood or other body ﬂuids, and its presence has been
detected in plasma only transiently, following a stroke [88].
Phosphorylated Tau Protein in DLB CSF. Since hyperphos-
phorylatedtauproteinoccursinneurodegenerativedisorders
associated with neuroﬁbrillary pathology, it is not surprising
that phosphorylated tau epitopes, for example, threonine
231 (p-tau231), threonine 181 (p-tau181), and serine 199
(p-tau199), have been recommended by a consensus group
as promising biomarkers to diﬀerentiate AD from other
dementias, provided that they have a sensitivity level of 85%
or greater and a speciﬁcity level of at least 75% [89]. These
posttranslational modiﬁcations of the tau protein have been
extensively assessed in various types of dementias, and in
particular how well they diﬀerentiate DLB from AD using
CSF samples [57]. These studies have indicated that p-
tau231 is the initial post-translational modiﬁcation of the
tau protein found in the CSF, potentially making it a key
biomarker in the early detection of tauopathies, for example,
AD [90].International Journal of Alzheimer’s Disease 5
Table 3: CSF biomarkers for DLB.
Study Biomarker(s) Technique No. of subjects No. of controls Results
Mollenhauer et al.
[51] α-synuclein Sandwich ELISA 38 DLB; 13 AD; 8
PD; 8 CJD
13 neurological
controls
In PD and DLB, α-synuclein levels
signiﬁcantly reduced (P = .0305)
compared to AD and control
subjects.
Mukaetova-Ladinska
et al. [45]
α-synuclein
γ-synuclein
IgG
Dot blot 5L B D ;9A D ;3
VaD 8
Postmortem ventricular CSF
analysis. Elevation of both α-a n d
γ-synucleins in AD, LBD, and VaD
compared to controls. An increase
in α-a n dγ-synucleins seen from
Braak stage III onwards. Results
not inﬂuenced by age at death or
postmortem delay.
Noguchi-Shinohara
et al. [46] α-synuclein ELISA Assay 16 DLB; 21 AD
(A subgroup of 13 DLB
patients matched for
duration of disease and
MMSE score to those
of the AD subjects)
α-synuclein levels do not diﬀer
between DLB and AD patients.
L o w e rl e v e l so fα-synuclein in CSF
correspond to DLB duration
(P<.05).
O h r f e l te ta l .[ 49] α-synuclein ELISA 15 DLB; 66 AD; 15
PD 55
Similar levels of α-synuclein in
PD, DLB, and control subjects,
whereas, in AD, α-synuclein levels
signiﬁcantly lower compared to
controls (P < .001). AD subjects
with MMSE <20 had signiﬁcantly
lower level of α-synuclein than AD
subjects with MMSE ≥20.
Spies et al. [48] α-synuclein ELISA 40 DLB; 131 AD;
39 FTD; VaD 28
Two groups: Group A
57 (aged >50); Group
B 55 healthy volunteers
No signiﬁcant diﬀerence in
α-synuclein levels between DLB,
A D ,F T D ,V a D ,o rc o n t r o ls u b j e c t s .
Ballard et al. [44] α-synuclein Western blot 12 DLB 9
Signiﬁcant lower levels of
α-synuclein in DLB compared to
controls (P <.05). Mildly
cognitively impaired DLB subjects
(MMSE>24) also had lower levels
than controls (P<.007).
Kasuga et al. [52]
α-synuclein/
t-tau/p-
tau181
/Aβ42
ELISA
34 DLB
(including 2
with SNCA
duplication);
31 AD; 21 other
dementias
(12 FTD; 2 PSP,
2 normal pressure
hydrocephalus;
2V a D ;
3 unclassiﬁed)
No control group
α-synuclein signiﬁcantly lower in
DLB than in AD (P<. 05) or other
dementias (P<. 01). CSF
α-synuclein levels correlated with
Aβ42 level in DLB only (r = 0.43;
P = .01). CSF t-tau and p-tau181
levels as well as Aβ40/Aβ42 ratio
levels signiﬁcantly lower in DLB in
relation to AD (P <.01), but
similar to other dementias.
Arai et al. [54] t-tau Sandwich ELISA 6D L B ;8F T D ;
6P S P ;3C B D
19 (data taken from
previous study)
Similar levels of tau in AD and
DLB (P=.78), but higher than in
controls.
P a r n e t te ta l .[ 55]
t-tau/p-
tau181
/Aβ42
HT7-AT270
Assay and ROC
analysis
43 DLB; 80 AD 40
Strong correlation between t-tau
and p-tau independent of
diagnostic group (r = 0.904). No
diﬀerences between DLB and AD
for Aβ42. The signiﬁcant increase
in p-tau181 in AD (P=.039) has
80% sensitivity at diﬀerentiating
between AD and DLB.6 International Journal of Alzheimer’s Disease
Table 3: Continued.
Study Biomarker(s) Technique No. of subjects No. of
controls Results
Clark et al. [56]
t-tau/Aβ40
/Aβ42 (includes
also postmortem
correlation)
ELISA
3D L B ;7 4A D
(including 4
genetic AD and
10 LBVAD); 10
FTD; 5 CJD; 3
GSS syndrome;
11 miscellaneous
neurologic
conditions
73
DLB subjects had 2-fold higher level of
t-tau in relation to controls, but
two-fold lower levels in relation to AD.
No diﬀerences in t-tau between
LBVAD and AD (P = .30). Aβ42
highly depleted in DLB in comparison
to both control (8-fold) and AD
(4.4-fold) subjects.
Hampel et al. [57] p-tau181/p-
tau231/p-tau199 ELISA
22 DLB; 108 AD;
24 FTD; 7 VaD;
22 OND
23
Decrease in p-tau199, p-tau231, and
p-tau181 (P<.001) in DLB compared
to AD, with similar levels to other
studied dementia groups.
Parnetti et al. [58] t-tau/p-tau181
/A b β42 ELISA 19 DLB; 23 AD;
20 PD; 8 PDD 20
DLB mean CSF t-tau levels
signiﬁcantly lower than in AD patients
(P = .039), but signiﬁcantly higher in
P D ,P D D ,o rc o n t r o ls u b j e c t s .
p-tau181 elevated in AD, but similar
between DLB, PD, and PDD groups.
Vanderstichel et al.
[59]
t-tau/ p-tau181
/A β42
ELISA
assay 60 DLB; 94 AD 60
∗∗
Higher levels of p-tau181 in AD than
in DLB and controls. p-tau181 was the
most statistically signiﬁcant single
variable of the 3 biomarkers to
discriminate between AD and DLB.
Simic et al. [60] t-tau/ p-tau181/
p-tau199
ELISA
assay
2D L B ;1 1A D ;5
FTD; 8 VaD 13
p-tau181 diﬀerentiates AD and DLB
with a sensitivity of 91% and a
speciﬁcity of 95%.
Koopman et al. [61]
(autopsy conﬁrmed
dementias)
t-tau/p-tau181
/Aβ42 ELISA
18 DLB; 95 AD;
10 FTD; 6 CJD;
16 VaD
No control
group
DLB group had similar level of t-tau,
p-tau181, and Aβ42 as the other
dementia groups (FTD, CJD, and
VaD); these dementia subjects had
signiﬁcantly lower t-tau (P = .025)
and p-tau (P <. 0001) and higher
Aβ42 (P = .001) in comparison to AD.
Mattson et et al. [62]
(autopsy conﬁrmed
dementias)
t-tau/p-tau181
/Aβ42 ELISA
750 MCI (420
stable MCI; 14
incipient DLB;
271 incipient AD;
28 incipient VaD;
7 incipient FTD;
10 other
dementias); 529
AD
304
MCI subjects who developed DLB had
signiﬁcantly lower levels of t-tau and
p-tau181 at baseline compared to AD
and incipient AD (P<. 01),
signiﬁcantly lower Aβ42 CSF levels in
relation to control (P<. 001), stable
MCI, and AD subjects (P<. 01).
Spies et al. [63] Aβ1-42/Aβ1-40/
t-tau/p-tau181 ELISA 16 DLB; 69 AD;
26 VaD; 27 FTD 47
Signiﬁcantly lower levels of Aβ40 in
DLB and VaD in relation to AD
(P<. 01). AD had similar Aβ40 level
to controls (P = .384). The
Aβ42/Aβ40 ratio signiﬁcantly lower in
AD in comparison to other dementia
groups (P<.001). Aβ42/Aβ40 ratio
improves diﬀerentiating AD from VaD,
DLB, and FTD than Aβ42 measures
alone (P <.01). Aβ42/Aβ40 ratio
performed equally well as the
combination of Aβ42, p-tau181, and
t-tau in diﬀerentiating AD from FTD
and non-AD dementias.International Journal of Alzheimer’s Disease 7
Table 3: Continued.
Study Biomarker(s) Technique No. of subjects No. of controls Results
Bibl et al. [64]A β peptides Aβ-SDS-PAGE/
immunoblot
21 DLB; 23 AD;
21 PDD 23
The signiﬁcant increase of a
novel peptide with an Aβ-like
immunoreactivity (Aβ1-40
∗)i n
DLB patients relative to PDD has
a sensitivity of 81% and a
speciﬁcity of 71% using a cut of
point of 0.954% but failed to be
classiﬁed as a sole biomarker.
Bibl et al. [65]A β peptides/tau
Aβ-SDS-PAGE/
immunoblot and
ELISAs for
Aβ1-42 and tau
25 probable
DLB; 18
probable AD
14
The ratio of Aβ1-42/Aβ1-38 and
Aβ1-42/Aβ1-37 when combined
with absolute tau levels produced
a diagnostic test with 100%
sensitivity and 92% speciﬁcity.
This ratio discriminated between
AD and DLB with a high
speciﬁcity (P=6.6×10−6).
Wada-Isoe et al.
[66, 67] Aβ42/p-tau 181 ELISA assay 22 DLB; 34 AD 37
No signiﬁcant diﬀerence in p-tau
levels in AD and DLB, but a
signiﬁcant increase in the
p-tau/Aβ42 ratio in AD in
comparison to DLB.
Vanderstichele
et al. [59] Aβ42 ELISA
6L B D ;3 9A D ;
10 other
dementias,
neurological
and psychiatric
disorder
patients∗
12
Signiﬁcant decrease in CSF Aβ42
levels in both AD (P <.000l) and
LBD (P=0.002), relative to the
control group.
Maetzler et al.
[18] Aβ42 ELISA
9 DLB; 12 PDD;
14 PD no
dementia
No control group
L o w e rl e v e l so fA β42 in DLB and
PDD compared to the
nondemented PD subjects
(P=.024). DLB-PIB-positive
subjects had lower levels than the
PIB-negative subjects (P=.044),
but similar Aβ42 levels to the
PIB-negative subjects who had
dementia (P=.42).
Bostr¨ om et al.
[68] Mg/Ca/Cu Mass
spectrometry 29 DLB 51
Levels of Mg/Ca/Cu increased in
CSF in DLB relative to controls,
although increases in Cu not
signiﬁcant. The CSF-Mg
concentration had a sensitivity of
93% and a speciﬁcity of 81% to
detect DLB.
Molina et al.
[69]
Nitric-oxide
metabolites
(L-arginine to
L-citrulline)
Ionic-exchange
chromatography 22 DLB 13
Not statistically signiﬁcant
diﬀerence in NO metabolite
concentration between DLB and
controls.
Molina et al.
[70]
Neurotransmitter
(NT) amino-acid
(AA) concentrations
Ion-exchange
chromatography 21 DLB 26
∗∗
No signiﬁcant diﬀerences
between control and DLB groups
in relation to glutamate,
aspartate, and GABA levels;
however, higher concentrations
of asparagine (+25%) and
glycine (+21%) in DLB.8 International Journal of Alzheimer’s Disease
Table 3: Continued.
Study Biomarker(s) Technique No. of subjects No. of controls Results
Schultz et al.
[71]
Cocaine- and
Amphetamine-
Regulated Transcript
(CART)
Radio-
immunoassay 12 DLB; 14 AD 12
Signiﬁcant decrease (30%) in CART
in DLB versus controls (P<. 0001),
DLB, and AD (P<. 05), but
concentrations of CART did not
indicate DLB progression. CART
levels correlated with p-tau protein
concentration.
Schultz et al.
[72] Transthyretin (TTR) Radio-
immunoassay 13 DLB; 59 AD 13
No signiﬁcant diﬀerences of TTR
concentrations between AD and
DLB.
Please note that ELISA assays for t-tau, p-tau, and Aβ42, unless otherwise speciﬁed, refer to commercially available sandwich ELISA assays.
Abbreviations: DLB: Dementia with Lewy bodies; LBD: Lewy Body disease; AD: Alzheimer’s Disease; LBVAD: Lewy Body variant of Alzheimer’s
disease; PD: Parkinson’s Disease; PDD: Parkinson disease dementia; CJD: Creutzfeldt-Jakob disease; GSS: Gerstmann-Straussler-Scheinker syndrome;
FTD: Frontotemporal dementia; VaD: Vascular Dementia; PSP: Progressive supranuclear palsy; OND: other neurologic disorders (e.g., mild psychiatric
or neurologic symptoms); CSF: Cerebrospinal ﬂuid; Aβ: Amyloid-beta peptide; t-tau: total tau; p-tau: phosphorylated tau; ELISA: Enzyme-Linked
Immunosorbent assay; Aβ-SDS-PAGE: Aβ-sodium dodecylsulphate-polyacrylamide gel electrophoresis; ROC: Receiver Operating Characteristic; MMSE:
Mini Mental State Examination; PIB: 11C-labelled amyloid ligand Pittsburgh Compound B.
∗Speciﬁcally vascular dementia (n = 3); hypoxia during cardiac arrest (n = 1 ) ;c e r e b r o v a s c u l a rl e s i o n( n = 1); unspeciﬁed dementia (n = 2); depression
(n = 3).
∗∗Age-matched control.
(a) (b) (c) (d) (e)
Figure 1: Neuropathological hallmarks of dementia. Senile plaques (a) containing amyloid protein and neuroﬁbrillary pathology (b)
consisting of altered tau protein are the hallmarks of Alzheimer’s disease and ageing. In dementia, loss of synaptic proteins aﬀects both
allo- and neocortical areas. In Dementia with Lewy body, intraneuronal aggregates of α-synuclein give rise to Lewy bodies ((d),(e)) that
are also found in normal ageing and in other neurodegenerative diseases, including AD and PDD. Light microscopy ((a), (d)); confocal
microscopy ((b), (c), (e)). Labelling: Bielschowsky silver (a), tau immunohistochemistry (b), synaptophysin labelling (c), and alpha-
synuclein immunohistochemistry ((d), (e)). Magniﬁcation: x100 (a) and x400 ((b)–(e)).
CSF p-tau181 in DLB. Although p-tau231 is a relatively
consistent biomarker of all dementias (including DLB),
increased concentrations of p-tau181 in the CSF appear to
be often implicated in DLB (see [91], Table 3). The CSF
elevation of p-tau181 is not restricted to DLB, but also found
in several other neurodegenerative disorders, thus reﬂecting
the presence of overlapping neuroﬁbrillary pathology. Nev-
ertheless, p-tau181 measures appear to be diﬀerent in the
two dementia types: AD subjects have signiﬁcantly higher
CSF level of p-tau181 compared to control and DLB subjects
(see [59]; Table 3), and this diﬀerentiates AD from DLB,
with a sensitivity of 91% and a speciﬁcity of 94% [60].
However, in autopsy-conﬁrmed AD, the diagnostic accuracy
ofCSF p-tau181todiscriminate ADfromDLBshowedlower
sensitivity and speciﬁcity (75% and 61%, respectively, and
73% diagnostic accuracy; see [61]).
The data from the latter study were similar to those of
Hampel et al. [57] which found an increase in p-tau181 CSF
measurestohaveasensitivityof94%andaspeciﬁcityof64%
for diﬀerentiating AD and DLB. However, the combination
of p-tau231 and p-tau199 did not produce promising results
in diﬀerentiating between these two dementia syndromes:
speciﬁcities of p-tau231 and p-tau199 were 64% and 50–
64%,respectively.Thelattermaybeduetothelowsensitivity
and speciﬁcity of p-tau199 CSF measures (both ranging
between 25–30%) in diﬀerentiating between AD, other
dementia subtypes, and control subjects [60].
CSF Total Tau and Relationship to p-tau Measures in DLB.
OneoftheearliestattemptsinevaluatingthepotentialofCSF
measures of total tau protein (t-tau) in dementia studies was
that by Arai et al. [54], which reported signiﬁcantly elevated
CSF t-tau protein levels in AD subjects in comparison to
PD patients (Table 3). In the follow-up study [92], CSF
t-tau levels were determined in a number of dementia
syndromes including FTD, progressive supranuclear palsy
(PSP), corticobasal degeneration (CBD), and DLB, as well
as a control group. Although CSF t-tau was elevated in theInternational Journal of Alzheimer’s Disease 9
Table 4: CSF studies in Parkinson’s disease.
Study Type(s) of
Biomarker
Sample(s)
taken
Type(s)
dementia
Almonti et al.
[73] Metals CSF PD
Asai et al.
[74] Orexin CSF PD
Bibl et al.
[75]
Amyloid-Beta/
Tau CSF/Plasma VaD
Compta et al.
[76]
Amyloid-Beta/
Tau CSF PD/PDD
Lunardi et al.
[77]
DA and
metabolites∗ CSF PD
Salehi and
Mashayekhi et al.
[78]
BDNF CSF PD
BDNF: Brain-Derived Neurotrophic Factor; DA: Dopamine; CSF: Cere-
brospinal ﬂuid; VaD: Vascular Dementia; PD: Parkinson’s Disease;
∗Homovanillic acid (HVA), Dihydroxyphenylacetic acid (DOPAC).
DLB group, there was no signiﬁcant diﬀerence between the
DLB and AD subjects (using the previous data from the AD
patients). In contrast, Parnetti et al. [55]r e p o rt e dd i ﬀerences
in both CSF t-tau and p-tau levels between AD and DLB
patients with a greater diﬀerence for the p-tau CSF (Table 3).
These ﬁndings of higher t-tau and p-tau CSF measures
in AD subjects in comparison to other forms of dementia
were conﬁrmed again in a later study by the same group (see
[58]; Table 3), with the DLB subjects, although having lower
t-tauthanAD(P =.039),stillexhibiting2-3foldhigherlevel
of CSF t-tau measures than those in PD, PDD, and control
subjects. Furthermore, data from this study indicated that, of
the19patientswithDLB,halfdisplayedhighlevelsoft-tauin
their CSF, similar to those of the AD subjects. Interestingly,
PD subjects with dementia also showed an elevation of t-
tau and p-tau compared with PD and control groups, and
this was also accompanied by a decrease in amyloid peptides
[76], similar to previous dementia studies. Similar ﬁndings
of highly elevated CSF t-tau and p-tau181 have now been
reported for some autopsy-conﬁrmed DLB patients [93].
Concentrations of both t-tau and p-tau do not correlate
with the DLB disease duration [58]. However, signiﬁcant
inverse correlation between t-tau levels and MMSE (r =
−0.54; P =.02) along with a Milan Overall Dementia
Assessment (MODA) (a standardised assessment for staging
dementia used globally but developed within Italian clinics
[94]) (r =− 0.66; P = .002) score has been reported, similar
to ﬁndings of a previous study [55]. One of the explanations
for this may be the signiﬁcantly lower levels of t-tau and p-
tau181 already present in incipient DLB [62], suggesting that
the cognitive changes may well be inﬂuenced by additional
factors, for example, neuronal cell loss, vascular insults, and
so forth.
CSF Tau Protein Changes in Autopsy-Proven DLB. The pres-
ence of LBs may have a damaging eﬀect upon the neuronal
cytoskeleton (reviewed in [36]), and thus, may contribute
to the altered levels of tau within the CSF in DLB subjects.
Indeed, elevated levels of CSF total-tau (considered a marker
of axonal neuronal damage) have been conﬁrmed in cases
with a deﬁnite diagnosis of AD, Lewy Body variant of AD,
as well as DLB alone (see [56]; Table 3), thus reﬂecting the
described impairment in axonal transport [95] and axonal
loss (reviewed in [96]) underlying the development of both
AD and LB pathologies. However, the CSF t-tau ﬁndings are
not conclusive, and a contrary report of a decrease in t-tau
in DLB was also described in a similar study conducted on
autopsy-conﬁrmed sample [61]. The latter may well reﬂect
the more advanced stages of the dementia disease process,
characterised by both generalised axonal and neuronal loss,
as reported previously (see [97], reviewed in [98]).
Recent correlative biochemical and neuropathological
studies have also highlighted the relationship between the
CSF tau measures (p-tau181 and p-tau231) with the extent
of brain neuroﬁbrillary pathology (e.g., neuritic plaques
and neocortical neuroﬁbrillary tangles) in AD subjects [99,
100], thus conﬁrming that the CSF tau protein measures
reﬂect closely the brain accumulation of the characteristic
AD hallmarks of the disease, the neuroﬁbrillary pathology.
However, the ﬁndings for CSF p-tau181 are not conclusive,
as previous studies have reported lack of association of
this CSF tau measurement with neuroﬁbrillary pathology
[101, 102]. The diﬀerences in the reports may arise from the
diﬀerencesintimingofobtainingtheCSFsamplesinrelation
to autopsy (ranging from approximately one year [101, 102]
to 6 years [99]), suggesting that the CSF p-tau measures
close to death do not necessarily reﬂect the true extent of
neuroﬁbrillary pathology in the brain, as detected using
immunohistochemical [101] or immunobiochemical [90]
methods, since the presence of end stages of neuroﬁbrillary
tangles (the so-called “ghost tangles”, consisting of the core
ofthepairedhelicalﬁlaments;see[103])couldnothavebeen
addressed.
2.1.3. Amyloid-Beta (Aβ)P e p t i d e sa saB i o m a r k e r
Aβ Processing. Aβ peptides play an important role not
only in the AD pathogenesis [104], but also in DLB. It is
suggested by interacting with α-synuclein that the amyloid
peptides promote aggregation, enhance the accumulation of
α-synuclein pathologies, and accelerate cognitive dysfunc-
tion [105]. It is, therefore, reasonable to examine amyloid
peptides for their potential diagnostic value in DLB.
CSF Aβ Peptides in DLB. The altered brain processing
of APP, leading to accumulation of extracellular amyloid
deposits throughout the brain tissue of the aﬀected indi-
viduals, is also seen in the periphery, for example, CSF
and blood/blood derivates. Thus, the CSF decrease of Aβ
peptide 1-42, although characteristic of AD, is also found
in DLB and PDD (see [64]; Table 3), and this may reﬂect
the similar extent of Aβ deposits in these diseases (reviewed
in [106]). In support of the latter are the recent ﬁndings of
CSF Aβ42 loss in DLB subjects being accompanied by lower
CSF levels of cystatin C [107], a peptide that inhibits ﬁbril
formation and oligomerization of the amyloid peptide [108].
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downregulating CSF Aβ42 levels comes from a PET imaging
study, which demonstrated that the PIB binding in DLB
was associated with cognitive impairment (P = .0006) and
decrease in CSF Aβ42 (P = .042; see [18]).
The shorter amyloid peptide (Aβ1-40) also appears to
be decreased in the CSF of AD subjects, and signiﬁcantly
more in those with a clinical diagnosis of DLB and vascular
dementia [48]. Furthermore, the ratio between the longer
and shorter CSF amyloid peptides (Aβ42/Aβ40) appears
to be superior in discriminating between AD and other
neurodegenerative disorders, including DLB, than the Aβ42
measure alone (P< .01), with the former being equally
robust as the combination of Aβ42, p-tau181, and t-tau (see
[63]; Table 3). In contrast, in AD (but not DLB and PDD)
there was a slight increase in CSF Aβ1-37 [64], and this
may reﬂect the slight diﬀerences in the Aβ brain deposition
between AD and DLB, in terms of the deposition occurring
later in the course of DLB [109] or the faster rate of disease
progression in DLB [32].
In the Bibl et al. [64]s t u d y ,an o v e lA β-like peptide
(considered to be an oxidised α-helical form of Aβ,d e s i g -
nated as Aβ1-40
∗) was detected in all recruited participants
(including the nondemented controls) and was signiﬁcantly
increasedinthoseaﬀectedbyDLB(incomparisonwithPDD
patients), and to a lesser degree in AD as compared to PDD
and control subjects. In fact, the CSF Aβ1-40
∗ measures
had 81% sensitivity and 71% speciﬁcity at diﬀerentiating
between DLB and PDD. Furthermore, the ratio of Aβ1-42 to
Aβ1-37 signiﬁcantly diﬀerentiated the control subjects from
those with DLB, PDD, and AD and diﬀerentiated the AD
subjects from those with DLB and PDD [64]. These ﬁndings
suggest that the Aβ CSF patterns vary between AD, DLB, and
PDD, and introduction of Aβ ratios improves the diagnostic
CSF test accuracy for the dementia diﬀerential diagnosis,
which is not the case when sole measurements of Aβ1-42
are reported. Similarly, the diﬀerential diagnostic value of
Aβ peptide patterns in combination with tau protein assays
appears to be improved. The ratio of Aβ1-42 to Aβ1-38 and
Aβ1-42 to Aβ1-37, when combined with t-tau levels, has
100% sensitivity and 92% speciﬁcity in diﬀerentiating AD
from DLB and control subjects [65].
A study by Parnetti et al. [58]i n v e s t i g a t e daw i d e r
range of subjects, including those with DLB, PD, PDD,
and AD. In comparison to PD, PDD, and AD subjects,
the DLB group had the lowest CSF level of Aβ42, and the
latter was negatively correlated with the dementia duration.
In addition, DLB patients had a signiﬁcantly higher t-tau
CSF measures relative to PD, PDD, and controls. However,
diﬀerences in CSF levels of p-tau, although signiﬁcantly
elevated in AD, failed to discriminate the disease entities
within the Lewy body disease (LBD) spectrum, irrespective
o fp r e s e n c eo fd e m e n t i a( D L B ,P D D ,o rP D ) .I ti si m p o r t a n t
to note that 4 out of 23 AD patients in this study had a CSF
analytes composition remarkably similar to that of the DLB
group.
The above set of data is similar to that of Vanderstichele
et al. [110]. The latter group reported a signiﬁcant decrease
in CSF Aβ42 in both AD (P< .001) and LBD (P =.002)
patients, relative to the control group (data for DLB subjects
were not extracted separately in this study). In contrast
to their previous ﬁndings [64], later CSF studies, further
supported by 123I-MIBG cardiac scintigraphy observations,
found no signiﬁcant diﬀerence in the CSF Aβ42 measures
between AD and DLB subjects [65, 67]. However, the cardiac
scintigraphy provided the best discrimination between the
two dementia groups. Thus, the DLB subjects had signiﬁcant
elevation of washout rate in comparison to both the AD and
control groups [67].
2.2. Miscellaneous Biomarkers
Inﬂammatory Markers. The biochemical and neuropatho-
logical studies in DLB have highlighted a number of novel
putative molecular candidates present in the CSF (Table 3).
Inﬂammation is associated with amyloid accumulation in
dementia [111], and inﬂammatory markers have also been
detected and investigated in the CSF. However, in DLB, the
interleukin CSF levels, speciﬁcally, IL-1β and IL-6, did not
discriminate DLB from control subjects [112]. Similarly,
CSF measures of the precursor peptides for enkephalins
and substance P (midregional proenkephalin A and N-
terminal protachykinin A, resp.), involved in inﬂammation
and pain, although decreased in dementia disorders, includ-
ing DLB, appear not to have the power to diﬀerentiate
various dementia syndromes from acute neuroinﬂammatory
disorders [113], suggesting that the CSF measures of these
two neuropeptide precursor fragments could reﬂect the
extent of neuroinﬂammation and reduction in neuronal
activity, common among these diseases.
CART Neuropeptides. The hypothalamic region in DLB
shows profound atrophy on MRI brain scans, and this may
underlie the characteristic ﬂuctuating clinical symptoms in
this dementia syndrome. Thus, any alterations in molecular
patterns associated with these characteristic morphological
changes can be useful in developing a biomarker for DLB.
The neuropeptide Cocaine and Amphetamine-Regulated
Transcript (CART) is expressed selectively in neurons in the
hypothalamicregion.AstudybySchultzetal.[71]reporteda
signiﬁcant reduction by 30% in the CSF CART levels in DLB
compared to both control and AD subjects. The depletion
of CART may be a causative factor in the dysfunction of the
dopaminergic system seen in DLB. Interestingly, CSF CART
levels correlate with p-tau protein levels, but they do not
appear to correlate with the DLB disease progression [71].
Thissuggeststhatneuroimagingtechniquesthatcoulddetect
dysfunctionofthedopaminergicsystem(aconsistentﬁnding
invariousDLBstudies[114])couldalsobeakeyinthefuture
diagnosis of DLB.
Brain Neurotransmitters. Brain neurotransmitters play an
essential role in various psychological and cognitive func-
tions. The relatively widespread cholinergic [115, 116]
and dopaminergic [117, 118] changes in DLB indicate a
more generalised neurotransmitter dysfunction that may
also be detected in the periphery. To test this hypothesis,
Molina et al. [70] measured the concentration of various
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changes within the CSF. Of these, levels of asparagine and
glycine, but not glutamate, glutamine, aspartate, and GABA,
were raised in both CSF and plasma from DLB patients
compared with age-matched controls, with only the plasma
levels reaching statistical signiﬁcance. This suggests that the
plasma measures of asparagine and glycine may be useful for
the DLB diagnosis. Interestingly, higher levels of glycine are
also found in other neurological disorders.
Posttranslational Protein Modiﬁcations. In vitro oxidation
and nitration of α-synuclein is associated with the aggrega-
tion of this protein [119], which leads to the characteristic
intraneuronal ﬁlamentous inclusions characteristic of DLB
pathology. Interestingly, a study conducted by Molina et al.
[69] found an increase in Nitric Oxide (NO), associated
with protein nitration processes, in CSF in DLB patients in
comparison to the control group. Not only does this give an
indication of further pathological processes within DLB, but
it also highlights the need for further research to determine
the clinical relevance of NO as a biomarker for the diagnosis
of DLB.
Markers of Cytoskeletal Changes. An increase in neuroﬁla-
ment (NF) in the CSF is also indicative of neuronal degen-
eration, as seen in neurodegenerative disorders, especially
AD. However, De Jong et al. [91] did not ﬁnd any NF
elevation within CSF of DLB patients relative to patients
aﬀected by late onset AD, despite an increase in cortical NF
containing neurons in DLB. This indicates that peripheral
NF concentration does not reﬂect the cortical NF expression.
One of the limitations of this study was the small sample
size and the lack of postmortem veriﬁcation of the diagnosis.
Further studies on larger clinical samples are now needed to
overcome these limitations.
Metal Homeostasis. Dysfunction in metal homeostasis has
been implicated as a causative factor for neurodegeneration.
I nas t u d yc o n d u c t e db yB o s t r o me ta l .[ 68]m e a s u r e m e n t s
of magnesium (Mg), calcium (Ca), iron (Fe), copper (Cu),
zinc (Zn), rubidium (Rb), strontium (Sr), and caesium (Cs)
were taken from the CSF samples. Ca and Mg levels were
elevated in DLB compared to AD, VaD, and control subjects.
In this study, the combined Ca and Mg CSF measurements
had a sensitivity of 93% and a speciﬁcity of 85% (using
cutoﬀ values of ≤48.0mg/L for Ca and ≤27.3mg/L for Mg)
to diﬀerentiate DLB from AD. Since clinical criteria state
that biomarkers must have a speciﬁcity and a sensitivity of
≥80%(asdiscussedabove[120]),thelatterﬁndingsmaywell
s u p p o r tt h eu s eo fC aa n dM gC S Fm e a s u r e sa sp o t e n t i a l
biomarkers for DLB.
Thyroid Hormone-Binding Protein Transporter of Thyroxine.
Transthyretin (TTR) changes are not only characteristic
for familial amyloid polyneuropathy, but also for other
neurodegenerative disorders, such as AD and dementia in
general [121]. It is thought that TTR has a “neuroprotective”
role in AD, via the prevention of formation of Aβ ﬁbrils.
Despite TTR proteins having a strong linkage with DLB-type
pathology, the study by Schultz et al. [72] did not ﬁnd any
correlation between CSF concentrations of TTR and clinical
presentation of DLB.
The clinical designs of the above studies (sample size,
inclusion criteria, diﬀerences in clinical assessments, number
of dementia types analysed, deﬁning control groups, etc.)
all diﬀered, and these diﬀerences need to be considered
when interpreting the results. With the exception of the
CSF measures of CART and metal compounds, there are no
putative biomarkers that emerge to diﬀerentiate DLB from
normal ageing and/or other types of dementia.
2.3. Additional CSF Biomarkers in Parkinson’s Disease (PD).
The overlapping clinical symptoms between DLB and PD
makethediﬀerentiationofthesetwoclinicalentitiesdiﬃcult.
Not surprisingly, our searches for DLB CSF biomarkers
highlighted a number of studies that included PD and PDD
subjects. While these studies may not ultimately highlight a
suitable biomarker for DLB, they should be considered, even
if only for evidence of further exclusion criteria.
BDNF. Brain-derivedneurotrophicfactor(BDNF)isimpor-
tant for sustaining existing neurons while promoting the
growth of new neurons. Therefore, depletion of BDNF
could account for the loss and damage of neurons during
various neurodegenerative disorders. In PD, elevated CSF
concentrations of BDNF relative to those of control subjects
have been reported [78]. Since BDNF is a signiﬁcant
mediator of PD pathology, its role should be assessed further
in other neurodegenerative conditions, speciﬁcally DLB due
to similarities with PD in terms of existing pathology.
Dopamine and Dopamine Metabolites. As discussed above
with respect to assessment of the transmitter system, indi-
rect measurement of Dopamine (DA) concentration via
its metabolites, Homovanillic acid (HVA), and Dihydrox-
yphenylacetic acid (DOPAC) may give additional infor-
mation about factors that contribute to the pathology of
neurodegenerative conditions where DA dysfunction occurs.
One particular study measured DA, HVA, and DOPAC in
diﬀerent stages of PD [77]. This study also reported an
exponential decrease of total DA in the CSF with disease
progression, with a rapid drop during the initial phases
of the disease onset, whereas an increased HVA/DA ratio
(whichindicatesDAturnover)correlatedlargelywithdisease
duration.
Hypocretin-1. Another potential biomarker highlighted due
to the recognition of sleep-related disorders in neurodegen-
erative conditions is hypocretin -1. This peptide was initially
associated with regulation of the sleep/wake cycle, along with
various autonomic dysfunctions. It has since been identiﬁed
in the CSF. A recent study conducted on PD subjects found
a 40% decrease of hypocretin-1 in the prefrontal cortex
and a 25% decrease in the ventricular CSF when compared
to controls [122]. Using CSF samples from a wider range
of neurological disorders, for example, DLB, progressive
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along with PD, can help to characterise the pathological
substrates of these sleep-related disorders [123]. However,
while sleep disorders are symptomatically linked with these
dementia syndromes, it seems as though one of the major
indicators of sleep dysfunction (the reduction of orexin) is
not altered in the CSF [74, 123].
Metals. Metals can contribute to both prooxidant and
antioxidant processes within the body. Investigations of
the substantia nigra in PD patients have demonstrated an
increase of iron (Fe), which, due to the production of free
radicals during its catalysis, could be a major contributor to
oxidative damage [124]. This makes it the metal of interest
when pursuing possible biomarkers for PD, along with
Chromium (Cr) and Lead (Pb), which have been linked
to PD cases. These three metals have been shown to be
signiﬁcantly reduced in CSF of PD patients relative to those
of the controls [73]. However, these observations have to be
evaluated in comparison to DLB patients.
3. Conclusions
Despite the neuroradiological advances aiding the clinical
diagnosis of distinct subtypes of dementias, their over-
lapping clinical and neuropathological features make clear
diﬀerentiation diﬃcult in clinical practice. Similarly, the
dementia clinical symptomatology varies from patient to
patient, along with disease progression and severity. This has
an impact on the pharmacological treatment and long-term
care of the aﬀected subjects. It is particularly important for
DLB patients who have severe side eﬀects to antipsychotic
medication.
Although a number of research studies provide evidence
that some of the investigated CSF biomarkers are well within
the clinical criteria for sensitivity and speciﬁcity (>90%),
they all seem to be characterised by the contradictory data
for each of the major groups of biomarkers: α-synuclein,
tau, and amyloid proteins. Similarly, results from the mis-
cellaneous biomarkers studies have proved disappointing
and nonconclusive. Having said that, a combination of CSF
measures appear to emerge, which may well be able to
diﬀerentiate DLB from other dementias: α-synuclein reduc-
tion in early DLB, a correlation between CSF α-synuclein
and Aβ42 measures (characteristic for DLB only), and t-tau
and p-tau181 proﬁle (diﬀerentiating AD from DLB). Their
usefulness in clinical setting needs to be explored further.
Identifying highly speciﬁc and sensitive peripheral ana-
lytes that reﬂect the key hallmarks of dementia that can be
used in clinical setting is an imperative. Such analytes have
been successfully identiﬁed for AD, having high sensitivity
and speciﬁcity in diﬀerentiating this neurodegenerative
disorder from other forms of dementia. Further work
concentrating on improving the currently available CSF α-
synuclein analytical tools may lead to further insights about
the peripheral α-synuclein processing, which, either alone,
or in a combination with known or novel analytes, may
aid the diﬀerential diagnosis of DLB. In this respect, CSF
proteomicstudies(reviewedin[125])haveprovidedpromis-
ing results, for example, identifying eight novel proteins
Table 5: Proteomic studies.
Study Technique(s)
used
Sample(s)
taken
Type(s) of
dementia
Abdi et al.
[79] iTRAQ CSF DLB/AD/PD
Basso et al.
[80]
MALDI-TOF-
MS SN tissue PD
Davidsson et al.
[81]
2D gel
electrophoresis CSF AD
Wada-Isoe et al.
[66]
SELDI-TOF-
MS Serum DLB/AD
Yin et al.
[82]
LC-MS/MS
and 2-DE CSF AD/PD
which can diﬀerentiate between AD, PD, and DLB with a
95% speciﬁcity and sensitivity (see [79]; Table 5). Similarly,
proteomic studies based on speciﬁc pathological features of
neurodegenerative conditions have also proved noteworthy.
By exploiting the fact that substantia nigra (SN) is the most
vulnerable region within the brain to be aﬀected by oxidative
stress, Basso et al. [80] collected postmortem tissue samples
from this region from subjects with PD and reported that
9 of the 44 proteins had a changed pattern of expression
in the PD patients compared with the controls. The most
signiﬁcant of these proteins was the upregulation of per-
oxiredoxin II, a characteristic indication of oxidative stress
(Entrez Gene).
Although promising, further DLB proteomic studies are
warranted for better methodological approaches to include
a larger number of well- deﬁned samples and be able
to address either the central or associated brain disease
(dementia) process(es) and how they are reﬂected in the
periphery (CSF, blood/blood derivates, and/or urine). Their
further testing in routine clinical settings, alongside with the
currently available clinical screening and diagnostic tools,
should enhance the early dementia diagnosis and also aid
the monitoring and therapeutic outcomes for DLB-aﬀected
subjects.
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